Other Corporate Information – Alligator Bioscience

2026-10-15

Invitation to Alligator Bioscience’s interim report call on 22 October 2026

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company whose principal asset is a financial interest i ...

2026-10-04

Regulatory

Johan Giléus, currently CFO, has been appointed CEO effective 1 January 2027 Søren Bregenholt will remain CEO until 31 Decembe ...

2026-09-29

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2026-09-22

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2026-09-21

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2026-08-20

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company whose principal asset is a financial interest i ...

2026-07-23

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2026-07-02

First patient dosed in an investigator-initiated trial evaluating intratumoral mitazalimab, with or without intratumoral nivolumab Study eva ...

2026-06-08

Lund, Sweden – 8 June 2026 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today comments on a recent update regarding patient ...